Activating mutations of the PIK3CA gene are observed in approximately 20%–30% of HER2+ breast cancers and 30%–35% of HR+ diseases43 and are associated with a poorer prognosis in clinical trials of HER2‐targeted therapy compared to wild‐type PIK3CA, especially when HR is also positive. Here, ERBB2 is linked to breast carcinoma.